NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$3.8b

Last Updated

2021/04/19 22:12 UTC

Data Sources

Company Financials +

Executive Summary

CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. More Details


Snowflake Analysis

Flawless balance sheet with reasonable growth potential.


Similar Companies

Share Price & News

How has CareDx's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CDNA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: CDNA's weekly volatility (11%) has been stable over the past year.


Market Performance


7 Day Return

2.0%

CDNA

3.3%

US Biotechs

1.3%

US Market


1 Year Return

215.5%

CDNA

22.3%

US Biotechs

53.8%

US Market

Return vs Industry: CDNA exceeded the US Biotechs industry which returned 22.3% over the past year.

Return vs Market: CDNA exceeded the US Market which returned 53.8% over the past year.


Shareholder returns

CDNAIndustryMarket
7 Day2.0%3.3%1.3%
30 Day5.8%-0.05%5.1%
90 Day-21.9%-4.7%8.9%
1 Year215.5%215.5%24.2%22.3%56.6%53.8%
3 Year671.3%671.3%32.3%25.8%64.4%53.6%
5 Year1,607.0%1,607.0%44.2%32.7%120.4%95.7%

Long-Term Price Volatility Vs. Market

How volatile is CareDx's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is CareDx undervalued compared to its fair value and its price relative to the market?

12.98x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: CDNA ($74.27) is trading above our estimate of fair value ($65.32)

Significantly Below Fair Value: CDNA is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: CDNA is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: CDNA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CDNA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CDNA is overvalued based on its PB Ratio (13.2x) compared to the US Biotechs industry average (3.7x).


Future Growth

How is CareDx forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

83.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CDNA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: CDNA is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CDNA's is expected to become profitable in the next 3 years.

Revenue vs Market: CDNA's revenue (18.7% per year) is forecast to grow faster than the US market (9.3% per year).

High Growth Revenue: CDNA's revenue (18.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CDNA's Return on Equity is forecast to be high in 3 years time


Past Performance

How has CareDx performed over the past 5 years?

3.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CDNA is currently unprofitable.

Growing Profit Margin: CDNA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CDNA is unprofitable, but has reduced losses over the past 5 years at a rate of 3.2% per year.

Accelerating Growth: Unable to compare CDNA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CDNA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.3%).


Return on Equity

High ROE: CDNA has a negative Return on Equity (-6.74%), as it is currently unprofitable.


Financial Health

How is CareDx's financial position?


Financial Position Analysis

Short Term Liabilities: CDNA's short term assets ($273.1M) exceed its short term liabilities ($69.2M).

Long Term Liabilities: CDNA's short term assets ($273.1M) exceed its long term liabilities ($21.6M).


Debt to Equity History and Analysis

Debt Level: CDNA is debt free.

Reducing Debt: CDNA has no debt compared to 5 years ago when its debt to equity ratio was 53.8%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable CDNA has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: CDNA is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 27.3% per year.


Dividend

What is CareDx current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CDNA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CDNA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CDNA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CDNA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CDNA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.3yrs

Average management tenure


CEO

Reg Seeto (48 yo)

0.42

Tenure

US$1,955,661

Compensation

Dr. Reginald Seeto, also known as Reg, M.D., MBBS, has been the President at CareDx, Inc. since November 26, 2018 and its Chief Executive Officer and Director since November 1, 2020. He served as Chief Bus...


CEO Compensation Analysis

Compensation vs Market: Reg's total compensation ($USD1.96M) is below average for companies of similar size in the US market ($USD5.16M).

Compensation vs Earnings: Reg's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: CDNA's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.


Board Members

Experienced Board: CDNA's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.9%.


Top Shareholders

Company Information

CareDx, Inc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: CareDx, Inc
  • Ticker: CDNA
  • Exchange: NasdaqGM
  • Founded: 1998
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$3.849b
  • Shares outstanding: 51.82m
  • Website: https://www.caredx.com

Number of Employees


Location

  • CareDx, Inc
  • 1 Tower Place
  • 9th Floor
  • South San Francisco
  • California
  • 94080
  • United States

Listings


Biography

CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/19 22:12
End of Day Share Price2021/04/19 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.